Javascript must be enabled to continue!
Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies
View through CrossRef
Abstract
Lewy body dementia is the second most common form of neurodegenerative dementia, following Alzheimer’s disease. This umbrella term encompasses dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). The distinction between these two conditions lies in the timing of the onset of cognitive impairment relative to motor symptoms. In DLB, cognitive impairment precedes or coincides with motor symptoms within the first year, whereas in PDD, cognitive decline occurs more than a year after the onset of motor symptoms. Clinically, in addition to cognitive decline, patients with Lewy body dementia have parkinsonism, visual hallucinations, and fluctuations of cognitive status. The pathological hallmark of this condition is the presence of Lewy bodies and Lewy neurites, collectively referred to as Lewy-related pathology. This is identical to Parkinson’s disease, where dementia is not observed. The principal component of Lewy-related pathology is α-synuclein, which classifies this disorder as an α-synucleinopathy. While Lewy-related pathology represents a later stage of α-synuclein aggregation, earlier stages involve α-synuclein oligomers. Emerging evidence suggests α-synuclein oligomers may be more toxic than Lewy-related pathology. In addition to α-synuclein pathology, previous studies frequently observed comorbid pathological conditions, including Alzheimer’s disease neuropathologic change, TAR DNA-binding protein 43 (TDP-43) pathology, and cerebral small vessel disease among others. In this review, we provide a comprehensive overview of the underlying pathologies for Lewy body dementia and their molecular mechanisms and clinical implications. We also discuss concepts including the prion-like propagation hypothesis of α-synuclein, α-synuclein strain hypothesis, and recent advances in machine learning algorithms for analyzing propagation patterns. The purpose of this manuscript is to elucidate these complex pathological conditions, advance our understanding of the disease, and improve diagnostic strategies.
Springer Science and Business Media LLC
Title: Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies
Description:
Abstract
Lewy body dementia is the second most common form of neurodegenerative dementia, following Alzheimer’s disease.
This umbrella term encompasses dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD).
The distinction between these two conditions lies in the timing of the onset of cognitive impairment relative to motor symptoms.
In DLB, cognitive impairment precedes or coincides with motor symptoms within the first year, whereas in PDD, cognitive decline occurs more than a year after the onset of motor symptoms.
Clinically, in addition to cognitive decline, patients with Lewy body dementia have parkinsonism, visual hallucinations, and fluctuations of cognitive status.
The pathological hallmark of this condition is the presence of Lewy bodies and Lewy neurites, collectively referred to as Lewy-related pathology.
This is identical to Parkinson’s disease, where dementia is not observed.
The principal component of Lewy-related pathology is α-synuclein, which classifies this disorder as an α-synucleinopathy.
While Lewy-related pathology represents a later stage of α-synuclein aggregation, earlier stages involve α-synuclein oligomers.
Emerging evidence suggests α-synuclein oligomers may be more toxic than Lewy-related pathology.
In addition to α-synuclein pathology, previous studies frequently observed comorbid pathological conditions, including Alzheimer’s disease neuropathologic change, TAR DNA-binding protein 43 (TDP-43) pathology, and cerebral small vessel disease among others.
In this review, we provide a comprehensive overview of the underlying pathologies for Lewy body dementia and their molecular mechanisms and clinical implications.
We also discuss concepts including the prion-like propagation hypothesis of α-synuclein, α-synuclein strain hypothesis, and recent advances in machine learning algorithms for analyzing propagation patterns.
The purpose of this manuscript is to elucidate these complex pathological conditions, advance our understanding of the disease, and improve diagnostic strategies.
Related Results
Tijelo u opusu Janka Polića Kamova
Tijelo u opusu Janka Polića Kamova
The doctoral disertation is dedicated to the concept of the body in the works of Janko Polić Kamov. The body is approached as a signifier system on the basis of which numerous and ...
Novel β-synuclein Rearrangements in tumor
Novel β-synuclein Rearrangements in tumor
Abstract
Purpose
The synuclein family includes a-, b-, g-synuclein and is predominantly expressed in neurons. a- and b-synuclein is mutated in Parkinson's disease and demen...
Lewy Bodies and the Mechanisms of Neuronal Cell Death inParkinson's Disease and Dementia withLewy Bodies
Lewy Bodies and the Mechanisms of Neuronal Cell Death inParkinson's Disease and Dementia withLewy Bodies
AbstractNeuronal loss in specific brain regions and neurons with intracellular inclusions termed Lewy bodies are the pathologic hallmark in both Parkinson's disease (PD) and dement...
Dementia In Old Age: Prevention, Intervention & Care
Dementia In Old Age: Prevention, Intervention & Care
The review & discussion of research articles, journals, and some books help us to understand dementia. This review article may help to understand What is dementia? How to preve...
Neuropathology, Genetics and Biomarkers of Synucleinopathies
Neuropathology, Genetics and Biomarkers of Synucleinopathies
Abstract
Synucleinopathies are clinically and pathologically heterogeneous disorders characterized by pathologic aggregates of α-synuclein in neurons and glia, in the form ...
p21-activated kinase 4 controls the aggregation of α-synuclein by reducing the monomeric and aggregated forms of α-synuclein: involvement of the E3 ubiquitin ligase NEDD4-1
p21-activated kinase 4 controls the aggregation of α-synuclein by reducing the monomeric and aggregated forms of α-synuclein: involvement of the E3 ubiquitin ligase NEDD4-1
AbstractAggregation of misfolded alpha-synuclein (α-synuclein) is a central player in the pathogenesis of neurodegenerative diseases. Therefore, the regulatory mechanism underlying...
Characterization and regulation of alpha-synuclein phosphorylation in enteric neurons under physiological conditions
Characterization and regulation of alpha-synuclein phosphorylation in enteric neurons under physiological conditions
Alpha-synuclein is a 140 aa neuronal protein pathologically and
genetically linked to Parkinson’s disease (PD). In PD, the major protein
modification of alpha-synuclein is phosphor...
Characterization and Regulation of Alpha‐Synuclein Phosphorylation in Enteric Neurons
Characterization and Regulation of Alpha‐Synuclein Phosphorylation in Enteric Neurons
ABSTRACT
Alpha‐synuclein is a 140 aa neuronal protein pathologically and genetically linked to Parkinson's disease (PD). In PD, the major pro...

